Cover Image
市場調查報告書

慢性心臟衰竭 (CHF) :市場預測與分析

Chronic Heart Failure Market and Forecast Analysis to 2024

出版商 Datamonitor Healthcare 商品編碼 603951
出版日期 內容資訊 英文 356 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
慢性心臟衰竭 (CHF) :市場預測與分析 Chronic Heart Failure Market and Forecast Analysis to 2024
出版日期: 2017年12月11日 內容資訊: 英文 356 Pages
簡介

本報告提供慢性心臟衰竭 (CHF) 治療藥市場相關調查分析,提供市場預測,治療,流行病學,上市藥,開發平台藥物趨勢等系統性資訊。

預測:慢性心臟衰竭 (CHF)

  • 摘要整理
  • 市場動態
  • 預測與未來趨勢
  • 市場定義·手法
  • 一次調查手法
  • 參考文獻
  • 產品簡介 (後期) :C-CURE
  • 產品簡介:CORLANOR
  • 產品簡介:ENTRESTO
  • 產品簡介 (後期) :FARXIGA
  • 產品簡介 (後期) :JARDIANCE
  • 產品簡介 (後期) :MPC-150-IM
  • 產品簡介 (後期) :XARELTO
  • 產品簡介 (後期) :OMECAMTIV MECARBIL
  • 產品簡介 (後期) :VERICIGUAT

治療:慢性心臟衰竭 (CHF)

  • 摘要整理
  • 一次調查手法
  • 疾病定義·診斷
  • 患者區分
  • 目前治療選擇
  • 處方趨勢:射血分數低
  • 處方趨勢:射血分數的維持
  • 遵守比率

流行病學:慢性心臟衰竭 (CHF)

  • 摘要整理
  • 疾病的背景
  • 手法
  • 預測
  • 流行病學者的考察
  • 優勢與限制
  • 參考文獻
  • 附錄

上市藥:慢性心臟衰竭 (CHF)

  • 摘要整理
  • 產品概要
  • ACE抑制劑
  • ARB
  • 乙型阻斷劑
  • arudosuteron拮抗劑
  • 其他藥劑分類
  • 產品簡介:CORLANOR
  • 產品簡介:ENTRESTO

開發平台:慢性心臟衰竭 (CHF)

  • 摘要整理
  • 臨床開發平台概要
  • 初期階段的機會
  • 產品簡介 (後期) :C-CURE
  • 產品簡介 (後期) :FARXIGA
  • 產品簡介 (後期) :JARDIANCE
  • 產品簡介 (後期) :MPC-150-IM
  • 產品簡介 (後期) :XARELTO
  • 產品簡介 (後期) :OMECAMTIV MECARBIL
  • 產品簡介 (後期) :VERICIGUAT
目錄
Product Code: DMKC12661

Disease Overview

Chronic heart failure (CHF) is a serious medical condition in which the heart is unable to adequately fill with and eject blood. CHF can result from functional abnormalities such as ventricular dysfunction or arrhythmias, but structural disorders of the heart muscle or valves are also common causes. While current therapies have helped to improve patient outcomes, CHF still remains a major public health issue and is associated with high mortality rates and a poor prognosis.

Market Snapshot

Entresto will be the main driver of growth within the chronic heart failure market during the forecast period.

Novel CHF treatments have yet to alter prescribing practices from traditional ACE inhibitors and beta blockers.

CHF prevalence rises with age, with 55-84 years comprising three-quarters of all diagnosed prevalent cases in adults.

Entresto has overcome initial barriers to uptake and has the potential to change CHF treatment practices.

Despite a full pipeline it is unlikely that any candidates have the potential to significantly change treatment practices.

TABLE OF CONTENTS

  • FORECAST: CHRONIC HEART FAILURE (Published on 11 December 2017)
  • EXECUTIVE SUMMARY
  • MARKET DYNAMICS
  • FORECAST AND FUTURE TRENDS
  • MARKET DEFINITION AND METHODOLOGY
  • PRIMARY RESEARCH METHODOLOGY
  • BIBLIOGRAPHY
  • PRODUCT PROFILE (LATE STAGE): C-CURE
  • PRODUCT PROFILE: CORLANOR
  • PRODUCT PROFILE: ENTRESTO
  • PRODUCT PROFILE (LATE STAGE): FARXIGA
  • PRODUCT PROFILE (LATE STAGE): JARDIANCE
  • PRODUCT PROFILE (LATE STAGE): MPC-150-IM
  • PRODUCT PROFILE (LATE STAGE): XARELTO
  • PRODUCT PROFILE (LATE STAGE): OMECAMTIV MECARBIL
  • PRODUCT PROFILE (LATE STAGE): VERICIGUAT
  • TREATMENT: CHRONIC HEART FAILURE (Published on 04 October 2017)
  • EXECUTIVE SUMMARY
  • PRIMARY RESEARCH METHODOLOGY
  • DISEASE DEFINITION AND DIAGNOSIS
  • PATIENT SEGMENTATION
  • CURRENT TREATMENT OPTIONS
  • PRESCRIBING TRENDS: CHF WITH REDUCED EJECTION FRACTION
  • PRESCRIBING TRENDS: CHF WITH PRESERVED EJECTION FRACTION
  • COMPLIANCE RATES
  • EPIDEMIOLOGY: CHRONIC HEART FAILURE (Published on 09 October 2017)
  • EXECUTIVE SUMMARY
  • DISEASE BACKGROUND
  • METHODOLOGY
  • FORECAST
  • EPIDEMIOLOGIST INSIGHT
  • STRENGTHS AND LIMITATIONS
  • BIBLIOGRAPHY
  • APPENDIX: ADDITIONAL SOURCES
  • MARKETED DRUGS: CHRONIC HEART FAILURE (Published on 11 December 2017)
  • EXECUTIVE SUMMARY
  • PRODUCT OVERVIEW
  • ANGIOTENSIN-CONVERTING ENZYME INHIBITORS
  • ANGIOTENSIN RECEPTOR BLOCKERS
  • BETA BLOCKERS
  • ALDOSTERONE ANTAGONISTS
  • OTHER DRUG CLASSES
  • PRODUCT PROFILE: CORLANOR
  • PRODUCT PROFILE: ENTRESTO
  • PIPELINE: CHRONIC HEART FAILURE (Published on 11 December 2017)
  • EXECUTIVE SUMMARY
  • CLINICAL PIPELINE OVERVIEW
  • PRODUCT PROFILE (LATE STAGE): C-CURE
  • PRODUCT PROFILE (LATE STAGE): FARXIGA
  • PRODUCT PROFILE (LATE STAGE): JARDIANCE
  • PRODUCT PROFILE (LATE STAGE): MPC-150-IM
  • PRODUCT PROFILE (LATE STAGE): XARELTO
  • PRODUCT PROFILE (LATE STAGE): OMECAMTIV MECARBIL
  • PRODUCT PROFILE (LATE STAGE): VERICIGUAT

LIST OF FIGURES

  • Figure 1: Chronic heart failure - current and future market dynamics analysis
  • Figure 2: Datamonitor Healthcare's assessment summary of key marketed and pipeline drugs for chronic heart failure
  • Figure 3: Chronic heart failure drug sales across the US, Japan, and five major EU markets, by country, 2017-26
  • Figure 4: Entresto sales for chronic heart failure across the US, Japan, and five major EU markets, by country, 2017-26
  • Figure 5: Sales of Jardiance and Farxiga in the US, Japan, and five major EU markets, 2017-26
  • Figure 6: Sales of generic ACE inhibitors and ARBs in the US, Japan, and five major EU markets, 2017-26
  • Figure 7: Sales of MPC-150-IM and C-Cure in the US, Japan, and five major EU markets, 2017-26
  • Figure 8: Sales of vericiguat and omecamtiv mecarbil in the US, Japan, and five major EU markets, 2017-26
  • Figure 9: Sales of Xarelto and rivaroxaban generics in the US, Japan, and five major EU markets, 2017-26
  • Figure 10: Chronic heart failure drug sales in the US, by class, 2017-26
  • Figure 11: Chronic heart failure drug sales in the five major EU markets, by country, 2017-26
  • Figure 12: Chronic heart failure drug sales in the five major EU markets, by class, 2017-26
  • Figure 13: Chronic heart failure drug sales in Japan, by class, 2017-26
  • Figure 14: Methodology flow for Datamonitor Healthcare's chronic heart failure forecast
  • Figure 15: Price sources and calculations, by country
  • Figure 16: C-Cure for chronic heart failure - SWOT analysis
  • Figure 17: Datamonitor Healthcare's drug assessment summary of C-Cure for chronic heart failure
  • Figure 18: Datamonitor Healthcare's drug assessment summary of C-Cure for chronic heart failure
  • Figure 19: C-Cure sales for chronic heart failure across the US, Japan, and five major EU markets, by country, 2017-26
  • Figure 20: Corlanor for chronic heart failure - SWOT analysis
  • Figure 21: Datamonitor Healthcare's drug assessment summary of Corlanor for chronic heart failure
  • Figure 22: Datamonitor Healthcare's drug assessment summary of Corlanor for chronic heart failure
  • Figure 23: Corlanor sales for chronic heart failure across the US, Japan, and five major EU markets, by country, 2017-26
  • Figure 24: Entresto for chronic heart failure - SWOT analysis
  • Figure 25: Datamonitor Healthcare's drug assessment summary of Entresto for chronic heart failure
  • Figure 26: Datamonitor Healthcare's drug assessment summary of Entresto for chronic heart failure
  • Figure 27: Entresto sales for chronic heart failure across the US, Japan, and five major EU markets, by country, 2017-26
  • Figure 28: Farxiga for chronic heart failure - SWOT analysis
  • Figure 29: Datamonitor Healthcare's drug assessment summary of Farxiga for chronic heart failure
  • Figure 30: Datamonitor Healthcare's drug assessment summary of Farxiga for chronic heart failure
  • Figure 31: Farxiga sales for chronic heart failure across the US, Japan, and five major EU markets, by country, 2017-26
  • Figure 32: Jardiance for chronic heart failure - SWOT analysis
  • Figure 33: Datamonitor Healthcare's drug assessment summary of Jardiance for chronic heart failure
  • Figure 34: Datamonitor Healthcare's drug assessment summary of Jardiance for chronic heart failure
  • Figure 35: Jardiance sales for chronic heart failure across the US, Japan, and five major EU markets, by country, 2017-26
  • Figure 36: MPC-150-IM for chronic heart failure - SWOT analysis
  • Figure 37: Datamonitor Healthcare's drug assessment summary of MPC-150-IM for chronic heart failure
  • Figure 38: Datamonitor Healthcare's drug assessment summary of MPC-150-IM for chronic heart failure
  • Figure 39: MPC-150-IM sales for chronic heart failure across the US, Japan, and five major EU markets, by country, 2017-26
  • Figure 40: Xarelto for chronic heart failure - SWOT analysis
  • Figure 41: Datamonitor Healthcare's drug assessment summary of Xarelto for chronic heart failure
  • Figure 42: Datamonitor Healthcare's drug assessment summary of Xarelto for chronic heart failure
  • Figure 43: Xarelto sales for chronic heart failure across the US, Japan, and five major EU markets, by country, 2017-26
  • Figure 44: Omecamtiv mecarbil for chronic heart failure - SWOT analysis
  • Figure 45: Datamonitor Healthcare's drug assessment summary of omecamtiv mecarbil for chronic heart failure
  • Figure 46: Datamonitor Healthcare's drug assessment summary of omecamtiv mecarbil for chronic heart failure
  • Figure 47: Omecamtiv mecarbil sales for chronic heart failure across the US, Japan, and five major EU markets, by country, 2017-26
  • Figure 48: Vericiguat for chronic heart failure - SWOT analysis
  • Figure 49: Datamonitor Healthcare's drug assessment summary of vericiguat for chronic heart failure
  • Figure 50: Datamonitor Healthcare's drug assessment summary of vericiguat for chronic heart failure
  • Figure 51: Vericiguat sales for chronic heart failure across the US, Japan, and five major EU markets, by country, 2017-26
  • Figure 52: Diagnostic flow chart for patients with suspected heart failure
  • Figure 53: Percentage incidence of co-morbidities among chronic heart failure patients in the US, Japan, and five major EU markets, by co-morbidity/risk factor
  • Figure 54: Percentage of CHF patients across the US, Japan, and five major EU markets who are over the age of 65, diagnosed with hypertension, or diagnosed with CAD
  • Figure 55: Percentage of CHF patients diagnosed with HFrEF and HFpEF across the US, Japan, and five major EU markets, by country
  • Figure 56: Percentage of patients with HFrEF in each NYHA class, by country
  • Figure 57: Percentage of patients with HFpEF in each NYHA class, by country
  • Figure 58: Percentage of HFrEF patients receiving each treatment type, by NYHA class
  • Figure 59: Percentage of regimens containing ACE inhibitors for the first-line treatment of HFrEF, by NYHA class and country
  • Figure 60: Percentage of regimens containing beta blockers for the first-line treatment of HFrEF, by NYHA class and country
  • Figure 61: Percentage of regimens containing ARBs for the first-line treatment of HFrEF, by NYHA class and country
  • Figure 62: Percentage of regimens containing ARBs for the treatment of HFrEF, by NYHA class and line of treatment
  • Figure 63: Percentage of regimens containing diuretics for the first-line treatment of HFrEF, by country and NYHA class
  • Figure 64: Percentage of regimens containing MRAs for the first-line treatment of HFrEF, by country and NYHA class
  • Figure 65: Percentage of regimens containing SGLT-2 inhibitors for the first-line treatment of HFrEF, by country and NYHA class
  • Figure 66: Percentage of regimens containing the SGLT-2 inhibitors Jardiance and Farxiga for the first-line treatment of HFrEF, by NYHA class
  • Figure 67: Top three drug regimens for first-line treatment of class I HFrEF, by country
  • Figure 68: Top three drug regimens for second-line treatment of class I HFrEF, by country
  • Figure 69: Top three drug regimens for first-line treatment of class II-III HFrEF, by country
  • Figure 70: Top three drug regimens for second-line treatment of class II-III HFrEF, by country
  • Figure 71: Top three drug regimens for first-line treatment of class IV HFrEF, by country
  • Figure 72: Top three drug regimens for second-line treatment of class IV HFrEF, by country
  • Figure 73: Percentage of HFpEF patients receiving each treatment type, by NYHA class
  • Figure 74: Percentage of regimens containing ACE inhibitors for the first-line treatment of HFpEF, by NYHA class and country
  • Figure 75: Percentage of regimens containing ARBs for the first-line treatment of HFpEF, by NYHA class and country
  • Figure 76: Percentage of regimens containing beta blockers for the first-line treatment of HFpEF, by country and NYHA class
  • Figure 77: Percentage of regimens containing diuretics for the first-line treatment of HFpEF, by country and NYHA class
  • Figure 78: Percentage of regimens containing MRAs for the first-line treatment of HFpEF, by country and NYHA class
  • Figure 79: Top three drug regimens for first-line treatment of class I HFpEF, by country
  • Figure 80: Top three drug regimens for second-line treatment of class I HFpEF, by country
  • Figure 81: Top three drug regimens for first-line treatment of class II-III HFpEF, by country
  • Figure 82: Top three drug regimens for second-line treatment of class II-III HFpEF, by country
  • Figure 83: Top three drug regimens for first-line treatment of class IV HFpEF, by country
  • Figure 84: Top three drug regimens for second-line treatment of class IV HFpEF, by country
  • Figure 85: Compliance rates of chronic heart failure patients in the US, Japan, and five major EU markets, by country and ejection fraction
  • Figure 86: Trends in diagnosed prevalent cases of CHF in the US, Japan, and five major EU markets, by country, 2016-36
  • Figure 87: Absolute change in diagnosed prevalent cases of CHF in the US, Japan, and five major EU markets, by country, 2016-36
  • Figure 88: Corlanor for chronic heart failure - SWOT analysis
  • Figure 89: Datamonitor Healthcare's drug assessment summary of Corlanor for chronic heart failure
  • Figure 90: Datamonitor Healthcare's drug assessment summary of Corlanor for chronic heart failure
  • Figure 91: Corlanor sales for chronic heart failure across the US, Japan, and five major EU markets, by country, 2017-26
  • Figure 92: Entresto for chronic heart failure - SWOT analysis
  • Figure 93: Datamonitor Healthcare's drug assessment summary of Entresto for chronic heart failure
  • Figure 94: Datamonitor Healthcare's drug assessment summary of Entresto for chronic heart failure
  • Figure 95: Entresto sales for chronic heart failure across the US, Japan, and five major EU markets, by country, 2017-26
  • Figure 96: C-Cure for chronic heart failure - SWOT analysis
  • Figure 97: Datamonitor Healthcare's drug assessment summary of C-Cure for chronic heart failure
  • Figure 98: Datamonitor Healthcare's drug assessment summary of C-Cure for chronic heart failure
  • Figure 99: C-Cure sales for chronic heart failure across the US, Japan, and five major EU markets, by country, 2017-26
  • Figure 100: Farxiga for chronic heart failure - SWOT analysis
  • Figure 101: Datamonitor Healthcare's drug assessment summary of Farxiga for chronic heart failure
  • Figure 102: Datamonitor Healthcare's drug assessment summary of Farxiga for chronic heart failure
  • Figure 103: Farxiga sales for chronic heart failure across the US, Japan, and five major EU markets, by country, 2017-26
  • Figure 104: Jardiance for chronic heart failure - SWOT analysis
  • Figure 105: Datamonitor Healthcare's drug assessment summary of Jardiance for chronic heart failure
  • Figure 106: Datamonitor Healthcare's drug assessment summary of Jardiance for chronic heart failure
  • Figure 107: Jardiance sales for chronic heart failure across the US, Japan, and five major EU markets, by country, 2017-26
  • Figure 108: MPC-150-IM for chronic heart failure - SWOT analysis
  • Figure 109: Datamonitor Healthcare's drug assessment summary of MPC-150-IM for chronic heart failure
  • Figure 110: Datamonitor Healthcare's drug assessment summary of MPC-150-IM for chronic heart failure
  • Figure 111: MPC-150-IM sales for chronic heart failure across the US, Japan, and five major EU markets, by country, 2017-26
  • Figure 112: Xarelto for chronic heart failure - SWOT analysis
  • Figure 113: Datamonitor Healthcare's drug assessment summary of Xarelto for chronic heart failure
  • Figure 114: Datamonitor Healthcare's drug assessment summary of Xarelto for chronic heart failure
  • Figure 115: Xarelto sales for chronic heart failure across the US, Japan, and five major EU markets, by country, 2017-26
  • Figure 116: Omecamtiv mecarbil for chronic heart failure - SWOT analysis
  • Figure 117: Datamonitor Healthcare's drug assessment summary of omecamtiv mecarbil for chronic heart failure
  • Figure 118: Datamonitor Healthcare's drug assessment summary of omecamtiv mecarbil for chronic heart failure
  • Figure 119: Omecamtiv mecarbil sales for chronic heart failure across the US, Japan, and five major EU markets, by country, 2017-26
  • Figure 120: Vericiguat for chronic heart failure - SWOT analysis
  • Figure 121: Datamonitor Healthcare's drug assessment summary of vericiguat for chronic heart failure
  • Figure 122: Datamonitor Healthcare's drug assessment summary of vericiguat for chronic heart failure
  • Figure 123: Vericiguat sales for chronic heart failure across the US, Japan, and five major EU markets, by country, 2017-26

LIST OF TABLES

  • Table 1: Chronic heart failure drug sales across the US, Japan, and five major EU markets, by country ($m), 2017-26
  • Table 2: Entresto sales for chronic heart failure across the US, Japan, and five major EU markets, by country ($m), 2017-26
  • Table 3: SGLT-2 inhibitor sales for chronic heart failure across the US, Japan, and five major EU markets, by country ($m), 2017-26
  • Table 4: Generic ACE inhibitor sales for chronic heart failure across the US, Japan, and five major EU markets, by country ($m), 2017-26
  • Table 5: Generic ARB sales for chronic heart failure across the US, Japan, and five major EU markets, by country ($m), 2017-26
  • Table 6: Generic ACE inhibitor patient numbers for chronic heart failure across the US, Japan, and five major EU markets, by country, 2017-26
  • Table 7: Generic ARB patient numbers for chronic heart failure across the US, Japan, and five major EU markets, by country, 2017-26
  • Table 8: Stem cell therapy sales for chronic heart failure across the US, Japan, and five major EU markets, by country ($m), 2017-26
  • Table 9: Stem cell therapy patient numbers for chronic heart failure across the US, Japan, and five major EU markets, by country, 2017-26
  • Table 10: Vericiguat sales for chronic heart failure across the US, Japan, and five major EU markets, by country ($m), 2017-26
  • Table 11: Omecamtiv mecarbil sales for chronic heart failure across the US, Japan, and five major EU markets, by country ($m), 2017-26
  • Table 12: Xarelto sales for chronic heart failure across the US, Japan, and five major EU markets, by country ($m), 2017-26
  • Table 13: Chronic heart failure drug sales across the US and five major EU markets, by country ($m), 2017-26
  • Table 14: Summary of drug classes and molecules included in Datamonitor Healthcare's chronic heart failure patient-based forecast
  • Table 15: Exchange rates used for calculating prices
  • Table 16: Cardiologists surveyed for the chronic heart failure primary research study, 2017
  • Table 17: C-Cure drug profile
  • Table 18: C-Cure's proposed Phase III trial design in chronic heart failure
  • Table 19: C-Cure completed late-phase data in chronic heart failure
  • Table 20: C-Cure sales for chronic heart failure across the US, Japan, and five major EU markets, by country ($m), 2017-26
  • Table 21: Corlanor drug profile
  • Table 22: Corlanor pivotal phase III trial data in chronic heart failure
  • Table 23: Corlanor Phase II trial data in chronic heart failure
  • Table 24: Corlanor sales for chronic heart failure across the US, Japan, and five major EU markets, by country ($m), 2017-26
  • Table 25: Entresto drug profile
  • Table 26: Entresto Phase III data in chronic heart failure
  • Table 27: Ongoing pivotal trials for Entresto in chronic heart failure
  • Table 28: Entresto sales for chronic heart failure across the US, Japan, and five major EU markets, by country ($m), 2017-26
  • Table 29: Farxiga drug profile
  • Table 30: Farxiga Phase III trials in chronic heart failure
  • Table 31: Farxiga sales for chronic heart failure across the US, Japan, and five major EU markets, by country ($m), 2017-26
  • Table 32: Jardiance drug profile
  • Table 33: Jardiance Phase III trials in chronic heart failure
  • Table 34: Jardiance sales for chronic heart failure across the US, Japan, and five major EU markets, by country ($m), 2017-26
  • Table 35: MPC-150-IM drug profile
  • Table 36: MPC-150-IM's late-phase trials in chronic heart failure
  • Table 37: MPC-150-IM sales for chronic heart failure across the US, Japan, and five major EU markets, by country ($m), 2017-26
  • Table 38: Xarelto drug profile
  • Table 39: Xarelto Phase III data in chronic heart failure
  • Table 40: Xarelto sales for chronic heart failure across the US, Japan, and five major EU markets, by country ($m), 2017-26
  • Table 41: Omecamtiv mecarbil drug profile
  • Table 42: Omecamtiv mecarbil Phase III study in chronic heart failure
  • Table 43: Omecamtiv mecarbil Phase II data in chronic heart failure
  • Table 44: Omecamtiv mecarbil sales for chronic heart failure across the US, Japan, and five major EU markets, by country ($m), 2017-26
  • Table 45: Vericiguat drug profile
  • Table 46: Vericiguat Phase III trials in chronic heart failure
  • Table 47: Vericiguat Phase II data in chronic heart failure
  • Table 48: Vericiguat sales for chronic heart failure across the US, Japan, and five major EU markets, by country ($m), 2017-26
  • Table 49: Cardiologists surveyed for the chronic heart failure primary research study, 2017
  • Table 50: Common laboratory test abnormalities in chronic heart failure
  • Table 51: Definitions of HFrEF and HFpEF
  • Table 52: New York Heart Association functional classification based on severity of symptoms and physical activity
  • Table 53: Comparison of ACCF/AHA stages of HF with NYHA functional classification
  • Table 54: Treatments available for chronic heart failure across the US, Japan, and five major EU markets
  • Table 55: NYHA functional classes I-IV, classification summary
  • Table 56: Sources used for the epidemiological analysis of CHF in the US, Japan, and five major EU markets, by country
  • Table 57: Diagnosed prevalent cases of CHF in the US, Japan, and five major EU markets, by country, 2016-36
  • Table 58: Age-specific diagnosed prevalent cases of CHF in the US, Japan, and five major EU markets, by country, 2016
  • Table 59: Gender-specific diagnosed prevalent cases of CHF in the US, Japan, and five major EU markets, by country, 2016
  • Table 60: Subtype-specific diagnosed prevalent cases of CHF in the US, Japan, and five major EU markets, by country, 2016
  • Table 61: Reduced EF diagnosed prevalent cases of CHF in the US, Japan, and five major EU markets, by country and NYHA class, 2016
  • Table 62: Preserved EF diagnosed prevalent cases of CHF in the US, Japan, and five major EU markets, by country and NYHA class, 2016
  • Table 63: Key marketed drugs for chronic heart failure
  • Table 64: Angiotensin-converting enzyme inhibitors class overview
  • Table 65: Angiotensin receptor blocker class overview
  • Table 66: Beta blocker class overview
  • Table 67: Aldosterone antagonists class overview
  • Table 68: Other drug class overview
  • Table 69: Corlanor drug profile
  • Table 70: Corlanor pivotal phase III trial data in chronic heart failure
  • Table 71: Corlanor Phase II trial data in chronic heart failure
  • Table 72: Corlanor sales for chronic heart failure across the US, Japan, and five major EU markets, by country ($m), 2017-26
  • Table 73: Entresto drug profile
  • Table 74: Entresto Phase III data in chronic heart failure
  • Table 75: Ongoing pivotal trials for Entresto in chronic heart failure
  • Table 76: Entresto sales for chronic heart failure across the US, Japan, and five major EU markets, by country ($m), 2017-26
  • Table 77: Profiled pipeline products in development for chronic heart failure
  • Table 78: C-Cure drug profile
  • Table 79: C-Cure's proposed Phase III trial design in chronic heart failure
  • Table 80: C-Cure completed late-phase data in chronic heart failure
  • Table 81: C-Cure sales for chronic heart failure across the US, Japan, and five major EU markets, by country ($m), 2017-26
  • Table 82: Farxiga drug profile
  • Table 83: Farxiga Phase III trials in chronic heart failure
  • Table 84: Farxiga sales for chronic heart failure across the US, Japan, and five major EU markets, by country ($m), 2017-26
  • Table 85: Jardiance drug profile
  • Table 86: Jardiance Phase III trials in chronic heart failure
  • Table 87: Jardiance sales for chronic heart failure across the US, Japan, and five major EU markets, by country ($m), 2017-26
  • Table 88: MPC-150-IM drug profile
  • Table 89: MPC-150-IM's late-phase trials in chronic heart failure
  • Table 90: MPC-150-IM sales for chronic heart failure across the US, Japan, and five major EU markets, by country ($m), 2017-26
  • Table 91: Xarelto drug profile
  • Table 92: Xarelto Phase III data in chronic heart failure
  • Table 93: Xarelto sales for chronic heart failure across the US, Japan, and five major EU markets, by country ($m), 2017-26
  • Table 94: Omecamtiv mecarbil drug profile
  • Table 95: Omecamtiv mecarbil Phase III study in chronic heart failure
  • Table 96: Omecamtiv mecarbil Phase II data in chronic heart failure
  • Table 97: Omecamtiv mecarbil sales for chronic heart failure across the US, Japan, and five major EU markets, by country ($m), 2017-26
  • Table 98: Vericiguat drug profile
  • Table 99: Vericiguat Phase III trials in chronic heart failure
  • Table 100: Vericiguat Phase II data in chronic heart failure
  • Table 101: Vericiguat sales for chronic heart failure across the US, Japan, and five major EU markets, by country ($m), 2017-26
Back to Top